Quantcast
Home > Quotes > RGEN
RGEN

Repligen Corporation Common Stock (RGEN) Quote & Summary Data

$49.5
*  
0.19
0.39%
Get RGEN Alerts
*Delayed - data as of Aug. 14, 2018  -  Find a broker to begin trading RGEN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RGEN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
50
Today's High / Low
$ 49.95 / $ 48.93
Share Volume
188,770
50 Day Avg. Daily Volume
330,171
Previous Close
$ 49.31
52 Week High / Low
$ 50 / $ 29.56
Market Cap
2,162,848,694
P/E Ratio
95.19
Forward P/E (1y)
69.45
Earnings Per Share (EPS)
$ 0.52
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.82

Intraday Chart

Shares Traded

Share Volume:
188,770
50 Day Avg. Daily Volume:
330,171

P/E Ratio

P/E Ratio:
95.19
Forward P/E (1y):
69.45
Earnings Per Share (EPS):
$ 0.52

Trading Range

The current last sale of $49.50 is 67.46% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 49.95 $ 50
 Low: $ 48.93 $ 29.56

ETFs with RGEN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.67% Invesco Dynamic Biotech & Genome ETF (PBE) +6.07 (11.72%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

The following discussion of our business contains forward-looking statements that involve risks and uncertainties. When used in this report, the words "intend," "anticipate," "believe," "estimate," "plan" and "expect" and similar expressions as they relate to us are included to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements and are a result of certain factors, including those set forth under "Risk Factors" and elsewhere in this Annual Report on Form 10-K. References throughout this Annual Report on Form 10-K to "Repligen", "we", "us", "our", or the "Company" refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates. Overview Repligen is a leading provider of advanced bioprocessing technology and solutions used in the process of manufacturing biologic drugs.  ... More ...  


Risk Grade

Where does RGEN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 49.28
Open Date:
Aug. 14, 2018
Close Price:
$ 49.50
Close Date:
Aug. 14, 2018

Consensus Recommendation

Analyst Info